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In a nomenclature proposal published in 2010 monocytes were subdivided into classical
and non-classical cells and in addition an intermediate monocyte subset was proposed.
Over the last couple of years many studies have analyzed these intermediate cells, their
characteristics have been described, and their expansion has been documented in many
clinical settings. While these cells appear to be in transition from classical to non-classical
monocytes and hence may not form a distinct cell population in a strict sense, their separate
analysis and enumeration is warranted in health and disease.
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IDENTIFICATION OF INTERMEDIATE MONOCYTES
Human monocyte subsets are typically analyzed in multi-color
flow cytometry using antibodies to CD14 (the LPS receptor) and
CD16 (the low affinity receptor for IgG; Passlick et al., 1989). A
dot blot histogram with the two markers demonstrates mono-
cytes with high CD14 expression and a population of cells with
co-expression of CD16 and of CD14 at a low level. The major
population of CD14++monocytes accounts for about 90% while
the CD16-positive cells account for about 10% of all monocytes
(Figure 1A)1. In the past, the very few cells with high CD14 and low
CD16, which are located between the two subsets (intermediates
in Figure 1B), have been allotted variously to the CD16-positive
or the CD14++monocytes (compare Figure 1A and Figure 1B).
However, over the years these intermediate monocytes (Figure 1B)
have gained recognition and they have been defined as a separate
cell population.
For definition of the intermediate monocytes these cells need
to be dissected from the non-classical and the classical monocytes.
The latter is straightforward since an isotype control can be used
to define the gating line (see Figures 2A,B).
What is more difficult is to draw the line between intermediates
and non-classical monocytes. Some investigators use an oblique
line such that the entire cloud of events of the CD14+CD16++
is enclosed (see Figure 2B), while others just draw a vertical
line to the left of the CD14 staining of the classical monocytes
(Figure 2C). While this latter approach has the advantage that it
can be executed automatically it cuts into the non-classical mono-
cytes. For an optimum separation of intermediate monocytes
1+Represents a fluorescence signal that is clearly separated from the negative control
staining,++ is a signal about 10-fold (1 log) stronger than+.
versus non-classical monocytes additional markers should be eval-
uated for defining the proper gate. Intermediate monocytes to date
have been analyzed in man and in non-human primates. There is
evidence that they also exist in other species like the mouse and
here their definition will likely also benefit from additional unique
markers.
CELLULAR AND MOLECULAR STUDIES
Recently Wong et al. (2011) divided the intermediate monocytes
further into three sub-regions of increasing CD16 expression
and demonstrated a continuum in staining for a whole set of
markers including CD64, CD115, CD163, CCR2, and CX3CR.
Also, microarray studies showed intermediate transcript levels for
almost 90% of all highly expressed genes. There was, however,
some evidence for unique properties in that CLEC10A, GDNF
family receptor alpha 2, and MHC class II genes were specif-
ically high in the intermediates compared to the classical and
non-classical monocytes (Wong et al., 2011).
Zawada et al. (2011) used SuperSAGE analysis and focused
on genes, which were selectively increased in the intermediates.
This included MHC class II genes and a whole series of addi-
tional genes like FAU, SECTM1, CTSB, and RHOB. Also they
noted that the mRNA for TIE2 (TEK, angiopoietin-2 receptor)
was not significantly increased in the intermediates but antibody
staining showed a specific twofold higher expression for TIE2
protein.
These data show that delineation of monocyte subsets cannot
be restricted to the transcript level but will have to take on board
all the other levels of gene expression including the proteome.
The Zawada findings of high TIE2 protein expression in the
intermediates is in line with earlier work by Murdoch et al. (2007)
and recent studies by Shantsila et al. (2011) and this indicates
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FIGURE 1 | Dot blot histograms from monocyte subpopulations using CD14 and CD16 markers. In (A) the conventional gating strategy is shown,
representing CD14++ and CD16-positive populations. In (B) a refined gating approach is given, which defines the intermediate monocytes in addition to
classical and non-classical monocytes.
FIGURE 2 | Dissection of intermediates from classical and non-classical
monocytes. In (A) the isotype control defines the separating line between
intermediates and classical monocytes. In (B) the dissection of intermediate
and non-classical monocytes is done with an oblique line to the right of the
cloud of non-classical events. In (C) a straight vertical line is placed to the left
hand end of the classical monocytes.
that cells previously termed TIE2-expressing monocytes strongly
overlap with and may be identical to the intermediate cells.
There have been transcriptome studies into intermediate
monocytes in non-human primates by Kim et al. (2010) and they
reported that among the 18 genes specifically up-regulated, the
matrix metalloproteinase-1 mRNA was found>50-fold higher in
the intermediates versus both the classical and the non-classical
monocytes. The three studies looking at the transcriptome of
intermediate monocytes in man and in non-human primates
found different genes to be selectively expressed in these cells.
This may be due to different technologies or to heterogeneity in
gene expression among the different (out-bred) individuals. Still,
the data on selective gene expression suggest that the intermediate
monocytes may play distinct functional roles in immune response
and inflammation.
FUNCTIONAL STUDIES
Most functional studies into monocyte subsets have looked at two
types of cells (classical and non-classical) with intermediate mono-
cytes being excluded or allotted to one or the other of the two main
monocyte types. However, a few studies specifically addressing
functions of the intermediates have been published.
Looking at cytokine production Skrzeczynska-Moncznik et al.
(2008) isolated intermediate monocytes based on CD14 and CD16
expression and they demonstrated highest IL-10 production in
these cells in response to LPS and to zymosan.
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Earlier functional studies by Grage-Griebenow et al. (2001)
defined the intermediate monocytes as CD64+ CD16+ cells
and demonstrated in this subset the highest capacity to present
antigen to T-cells. Here the intermediates were superior with
respect to antigen-specific induction of IL-12 and IFNgamma
and with respect to induction of alloantigen-induced T-cell
proliferation. Zawada et al. (2011) confirmed this in showing
that the intermediates have a slightly higher capacity to induce
superantigen-mediated T-cell proliferation.
Also, studies in an angiogenesis in vitro model revealed a selec-
tive cluster formation for the intermediate monocytes. Together
with the selective increase of TIE2 protein expression and a simi-
lar increase of endoglin and VEGF receptor 2 by the intermediates
(Zawada et al., 2011) this suggests a specific role in angiogenesis
for these cells. In line with this concept, work on TIE2-expressing
monocytes in the mouse has shown that among blood mononu-
clear cells only these cells are capable of inducing a capillary
network (De Palma et al., 2005).
Monocytes are precursors for dendritic cells and macrophages.
For the non-classical monocytes a higher propensity to become
DCs with a higher capacity to induce T-cell proliferation and IL-4
in CD4 T-cells has been reported (Randolph et al., 2002; Bajana
et al., 2007). Also recently it was demonstrated that macrophages
generated from CD16-positive monocytes (isolated by no-touch
procedures) maintain a differential expression pattern and show
higher phagocytosis activity when compared with macrophages,
which were derived from the classical monocytes (Frankenberger
et al., 2012). It is still unclear whether the intermediate mono-
cytes just represent a transitional type of cell or whether they
are a clearly distinct cell population. One way to address this
is to purify the CD14++CD16+ intermediate monocytes and
determine whether with in vitro culture they develop into non-
classical monocytes or into a unique progeny, which is different
from the progeny of classical or non-classical monocytes. If it
can be demonstrated that intermediate monocytes give rise to
a unique type of DC or macrophage then this would support
the concept that they are a biologically meaningful monocyte
subpopulation.
CLINICAL STUDIES
In clinical settings the intermediate monocytes have been noted
to increase in number in several diseases (for a detailed review,
see Wong et al., 2012). In asthma a pronounced increase of the
intermediates was seen in moderate and severe forms (Moniuszko
et al., 2009). When such patients were challenged with inhala-
tion of allergen, the numbers of intermediates decreased, and the
patients responded with bronchoconstriction (Kowal et al., 2012).
This would be in line with a scenario, in which upon allergen chal-
lenge the intermediates migrate into the lung and contribute to
bronchoconstriction.
For rheumatoid arthritis Cooper et al. (2012) noted a strong
increase of intermediates with a concomitant decrease of classical
monocytes. They also showed that high levels of the intermediates
predicted reduced response to therapy. In patients with colorec-
tal cancer the percentage of intermediate monocytes was found
increased and this was more pronounced in local than in metastatic
disease (Schauer et al., 2012).
FIGURE 3 |Time course of monocyte subpopulations during natural
infection. Blood samples were taken from a control donor and on
consecutive days from a patient with skin infection by beta-hemolytic
streptococci group A (erysipelas). First symptoms of lower limb
inflammation occurred on day 2, day 1 is the day of admission to hospital.
The flow cytometry setting was such that a high signal to noise ratio for
CD16 allowed for clear display of the intermediate monocytes. Taken from
thesis work of Alexia Horelt, Faculty of Medicine, Ludwig-Maximilians
University of Munich, 2003. Other parts of the thesis have been published
in Horelt et al. (2002).
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In adult survivors of childhood acute lymphoblastic leukemia
intermediate monocytes were found increased along with
increases of several inflammatory markers (Sulicka et al., 2013)
and this was suggested to contribute to the increased atherogen-
esis seen in these patients. In fact, intermediate monocytes were
found to predict cardiovascular events in dialysis patients (Heine
et al., 2008), which have a high risk of such events (reviewed in
Heine et al., 2012). The predictive power of these cells was con-
firmed by the same team in a general at-risk population (Rogacev
et al., 2012). Also, intermediates were found to be elevated in ST-
elevation myocard infarct with a peak on day 1 post the event
(Bajana et al., 2007; Tapp et al., 2012). Also, in stroke patients
the intermediates were reported to increase by day 2 and they
were predictive of subsequent infections (Urra et al., 2009). Fur-
thermore, the same study demonstrated that the numbers of
these monocytes were inversely related to mortality, i.e., high
numbers of intermediate monocytes went along with better sur-
vival. Such acute and dramatic events like a myocard infarct or a
stroke are associated with a stress response and studies into non-
classical monocytes have shown that catecholamines can lead to
an expansion of these cells (Steppich et al., 2000; Kittner et al.,
2002). It remains to be shown whether catecholamines play a
role in the increase of intermediate monocytes in stroke or MI,
as well.
When testing M-CSF in preclinical trials Weiner et al. (1994)
have noted a strong expansion of non-classical monocytes and
it was evident in those early studies that initially there was an
expansion of the intermediate monocytes. Also, histograms shown
by Saleh et al. (1995) suggest an expansion of the intermedi-
ates by M-CSF. Conversely, anti-M-CSF treatment was recently
shown to deplete both non-classical and intermediate monocytes
in man (Korkosz et al., 2012). When these cells recover over
a 4-week period of time then first the intermediate monocytes
reappear followed by the non-classical monocytes (Korkosz et al.,
2012).
In a model of viral infection, injection of the TLR7/8 lig-
and R-848 into non-human primates was shown to lead to a
strong increase in intermediate monocytes on day 1 followed by
a peak of non-classical monocytes on day 2 (Kwissa et al., 2012).
These data also support the transitional nature of the interme-
diate monocytes. Another example illustrating this transition in
the setting of a natural bacterial infection in a patient is seen in
Figure 3. Here the day 1 sample shows an increase of the interme-
diate cells compared to control with most CD16-positive events
located in the area of the line which in healthy individuals sep-
arate intermediates and non-classical monocytes. On day 2 cells
shift further to the left and the window for intermediate mono-
cytes clears up. Finally, on day 3 intermediates are back to normal
and the CD16-positive monocytes have their peak in the center of
the non-classical window.
Whether or not the intermediate monocytes, induced by var-
ious stimuli, go on to develop into non-classical monocytes may
be dependent on the type and on the strength of the stimulus.
When comparing gene expression patterns in classical and non-
classical monocytes for man versus mouse it was noted that a
differential gene expression between the two subsets was reverse
in man and mouse for a number of biologically relevant genes
(Ingersoll et al., 2010). Still, the mouse can serve as a model for
human blood monocyte subsets. While the intermediate mono-
cytes have been described in the mouse (Sunderkötter et al., 2004),
the potential of this model for the analysis of these monocytes still
needs to be exploited.
CONCLUDING REMARKS
Since the discovery of the CD16-positive monocytes by flow
cytometry this approach has been used to distinguish these cells
from the major population of classical monocytes. A third pop-
ulation of intermediate monocytes initially had been overlooked
because of its low number and transitional nature. Now clinical
studies have demonstrated that these cells can strongly expand
and laboratory analyses have shown intermediate but also unique
features for these cells. Specific markers for the intermediate
monocytes will be required in order to unequivocally identify and
enumerate these cells.
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